Chloe Chepigin

Chloe Chepigin supports clients with research and analysis spanning a variety of healthcare sectors and stakeholders.

She applies her background in drug pricing legislation, vaccine development, and health economics to advise a range of clients on diverse healthcare policy issues.

Prior to joining Avalere, Chloe supported the development of the World Health Organization’s National Assessment Tool for the Sustainable Local Production of Influenza Vaccines and produced the final progress report for the Global Action Plan for Influenza Vaccines. Additionally, she worked with the Office of Connecticut State Representative Sean Scanlon, where she collaborated with state legislators to develop bills concerning drug pricing transparency, access to essential health benefits, and value-based insurance design.

Chloe has an MPH from Yale School of Public Health and a BA in public health and international relations from the University of Rochester.

Authored Content

With a robust vaccines pipeline and opportunities to improve adult vaccine access, vaccines are currently a hot topic. In our 30-minute Conversations series, Avalere’s experts will break down the issues surrounding vaccines, what those issues mean, and their impact on various healthcare stakeholders. They will also provide insights on what to expect from the Advisory Committee on Immunization Practice’s meeting scheduled for June 26–27.

Avalere experts recently presented “A Comprehensive Analysis of Influenza Vaccine Uptake in Medicare” at the National Adult and Influenza Immunization Summit in Atlanta, GA.

Nearly 80,000 people died during the 2017–2018 influenza season. Only 37% of adults were vaccinated. Several novel emerging products could make vaccination more accessible and effective, potentially reshaping the market and lowering influenza disease burden.